Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 7/20 | 0.51 |
| ▸ | TPO | P07202 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.41 |
| ▸ | PDE4A | P27815 | 5/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | PDE1A | P54750 | 2/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284153 | 0.82 | MPO (0.54) | MPOTPOCYP3A4KCNH2ADORA2A | |
| SCHEMBL31025182 | 0.79 | MPO (0.56) | MPOTPOCYP3A4KCNH2ADORA2A | |
| SCHEMBL2285832 | 0.79 | MPO (0.56) | MPOTPOCYP3A4KCNH2ADORA2A | |
| SCHEMBL4166941 | 0.78 | MPO (0.60) | MPOTPOCYP3A4KCNH2ADORA2A | |
| SCHEMBL2283546 | 0.78 | MPO (0.57) | MPOTPOCYP3A4KCNH2ADORA2A | |
| SCHEMBL10187822 | 0.77 | MPO (0.56) | MPOTPOCYP3A4KCNH2ADORA2A | |
| SCHEMBL2288054 | 0.77 | MPO (0.53) | MPOTPOCYP3A4KCNH2ADORA2A | |
| SCHEMBL14740525 | 0.77 | MPO (0.51) | MPOTPOCYP3A4KCNH2ADORA2A | |
| SCHEMBL2282550 | 0.77 | MPO (0.52) | MPOTPOCYP3A4KCNH2ADORA2A | |
| SCHEMBL21632689 | 0.77 | MPO (0.52) | MPOTPOCYP3A4KCNH2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2013-03-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | MPO 1/4885TPO 87/4885CYP3A4 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.